ONWARD® Medical与CEA签署协议，获得Clinatec的WIMAGINE®脑机接口（BCI）技术的独家授权。

ONWARD® Medical signe un accord avec le CEA pour obtenir les droits exclusifs de la technologie d’interface cerveau machine (BCI) WIMAGINE® de Clinatec

CEA Enterprise 2024-10-15 10:00 Original
摘要
ONWARD Medical公司获得独家授权，将CEA研究人员开发的WIMAGINE®脑机接口集成至其ARC-BCI™系统。该协议使其有望率先推出通过脑机接口实现意念控制运动恢复的瘫痪治疗系统。

瑞士医疗科技公司ONWARD® Medical近日与法国原子能和替代能源委员会（CEA）签署协议，获得其旗下Clinatec研究所开发的WIMAGINE®脑机接口（BCI）技术的独家授权。该技术将被整合至ONWARD® Medical的ARC-BCI™神经刺激系统中。

此次合作旨在开发全球首款通过脑机接口驱动的医疗系统，帮助瘫痪患者通过思维控制恢复肢体运动。WIMAGINE®是一种植入式皮层脑电图（ECoG）设备，能够高精度解码大脑运动信号。ONWARD® Medical计划将其与ARC™脊髓刺激技术结合，构建完整的“大脑-脊柱”数字桥梁。

协议条款规定，ONWARD® Medical将获得WIMAGINE®技术的全球独家开发和商业化权利。双方将共同推进临床研究，加速该创新疗法获批上市。这一合作标志着脑机接口技术在临床康复领域迈出关键一步，有望为脊髓损伤患者带来革命性治疗方案。

Summary
ONWARD Medical has secured exclusive rights to integrate the WIMAGINE® brain-computer interface, developed by CEA researchers, into its ARC-BCI™ system. This agreement positions ONWARD to potentially be the first to market with a BCI-enabled system designed to restore thought-guided movement for people with paralysis.

ONWARD Medical has secured exclusive rights to integrate the WIMAGINE brain-computer interface (BCI) technology, developed by CEA researchers at Clinatec, into its own ARC-BCI™ system. This agreement positions the company to potentially launch the first market-ready BCI-activated system designed to restore movement through thought for individuals with paralysis.

The WIMAGINE technology, a key innovation from the French Atomic Energy and Alternative Energies Commission (CEA), will now be exclusively licensed to ONWARD for this application. The integration aims to combine WIMAGINE's neural signal recording capabilities with ONWARD's ARC-BCI platform, which delivers targeted spinal cord stimulation.

This strategic licensing deal accelerates ONWARD's pathway to commercializing a complete, implantable BCI system. The goal is to enable thought-controlled movement restoration, representing a significant advance in neurotechnology for paralysis treatment.

Résumé
ONWARD Medical acquiert les droits exclusifs d'intégrer l'interface neuronale WIMAGINE du CEA dans son système ARC-BCI. Cela positionne l'entreprise pour être la première à commercialiser un système activé par la pensée destiné à restaurer le mouvement après une paralysie. Cet accord marque une étape importante vers des thérapies de réhabilitation médicale innovantes.

​L'entreprise ONWARD® Medical obtient les droits exclusifs pour intégrer l’interface cerveau machine (BCI), WIMAGINE®, développée par des chercheurs CEA, dans son système ARC-BCI™. Cet accord offre à ONWARD® Medical l'opportunité d'être le premier sur le marché avec un système activé par BCI pour restaurer les mouvements guidés par la pensée après une paralysie.

AI Insight
中文 EN
Core Point

ONWARD Medical secured exclusive rights to integrate CEA’s WIMAGINE brain-computer interface into its ARC-BCI system, positioning it to be first to market with thought-controlled movement restoration for paralysis.

Key Players

ONWARD Medical — neurotechnology company, based in the Netherlands/Switzerland.

CEA — French public research organization, based in France.

Clinatec — medical technology research center, based in Grenoble, France.

Industry Impact
  • Computing/AI: High — BCI integration depends on advanced signal processing and neural decoding.
  • ICT: Medium — strengthens human-machine interface and connected medical systems.
  • Energy: Low — no direct impact, but relevant to implantable device power constraints.
Tracking

Strongly track — exclusive BCI rights could create a first-mover advantage in neurorehabilitation and medical neurotech.

Highlights
Investment / Funding
Related Companies
CEA-Leti
CEA-Leti mature
positive
positive
Categories
人工智能 生物技术 创业
AI Processing
2026-03-31 11:01
deepseek / deepseek-chat